Oncology

PharMerica Acquires McGuire Group Pharmacy

LOUISVILLE, Ky.–(BUSINESS WIRE)–PharMerica Corporation (NYSE:PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, announced today that it has completed the acquisition of McGuire Group Pharmacy (“McGuire”). Terms of the transaction were not disclosed. McGuire provides comprehensive pharmacy services to long-term care facilities and other customers …

Read More »

NeoGenomics to Acquire Clarient for $275 Million

FORT MYERS, Fla., Oct. 21, 2015 /PRNewswire/ — NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has reached an agreement to acquire Clarient, Inc., and its wholly-owned subsidiary Clarient Diagnostic Services, Inc., a provider of comprehensive cancer diagnostic testing to hospitals, physicians …

Read More »

Novartis Expands its Immuno-Oncology Pipeline through Acquisitions and Licensing Agreements

Basel, October 21, 2015 – Novartis announced today that it is broadening its portfolio of cancer immunotherapies with the acquisition of Admune Therapeutics and licensing agreements with Palobiofarma and XOMA Corporation. With four candidates currently in clinical trials and five more agents expected to enter the clinic by the end …

Read More »

Metamark’s Novel Prognostic Test Demonstrates Potential to be Cost-Effective for Management of Prostate Cancer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Metamark Genetics, Inc. (“Metamark” or the “Company”), a leader in commercializing high-value urologic oncology products, today announced that a study published in The Oncologist demonstrates that use of its novel proteomic prognostic test ProMark®, for early-stage prostate cancer, is likely to result in more cost-effective care than the National …

Read More »

Pfizer’s ALL Drug Receives Breakthrough Therapy Designation

Pfizer Inc. today announced that investigational antibody-drug conjugate (ADC) inotuzumab ozogamicin received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for acute lymphoblastic leukemia (ALL). The Breakthrough Therapy designation was based on the results of the Phase 3 INO-VATE ALL trial, which enrolled 326 adult patients with …

Read More »

Organ Transplant Drug Linked to Increased Risk of Rare Lymphoma

A study led by Johns Hopkins researchers has linked the immunosuppressive drug mycophenolate mofetil (MMF) to an increased risk of central nervous system (CNS) lymphoma in solid organ transplant patients. But the same study also found that another class of immunosuppressive drugs, called calcineurin inhibitors (CNIs), given alone or in …

Read More »

Bristol-Myers and Five Prime Sign Licensing Deal of up to $1.74 Billion

NEW YORK & SOUTH SAN FRANCISCO, Calif, Oct 15, 2015 (BUSINESS WIRE) — Bristol-Myers Squibb Company BMY, -0.02% and Five Prime Therapeutics, Inc. FPRX, +64.52% today announced that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Prime’s colony stimulating factor …

Read More »

Opko Health and Vanderbilt Collaborate on Genomics Testing

MIAMI–(BUSINESS WIRE)–OPKO Health, Inc. (NYSE:OPK) announced today a collaboration among its subsidiary, BioReference Laboratories, Inc., the Department of Pathology, Microbiology, and Immunology and the Vanderbilt-Ingram Cancer Center (VICC) at Vanderbilt University Medical Center (VUMC) to leverage large scale genomics testing for optimal cancer care. Each of the organizations has committed …

Read More »